Skip to content

Immunovant

US · IMVT #1790 by market cap Listed 2017
31.77 -0.75 -2.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 32.08 -1.35%
After-hours 31.51 -0.82%
Overnight 32.52 0.00%
44.9626.7331.772026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IMVT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +5.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -64.8% Better than 7%
Return on invested capital -66.8% Better than 4%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -28.4% Better than 19%
6-month return -7.0% Better than 44%
12-month return (ex latest month) 28.8% Better than 68%
Distance below 52-week high 30.1% Better than 43%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 9.1x Better than 93%
Debt to assets 0.0% Better than 100%
Interest coverage -105.1x Better than 5%
Analyst View B

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 75.0% Better than 51%
Upside to average target 52.4% Better than 68%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.05%
1M +11.12%
3M -28.37%
6M -10.66%
YTD +24.98%
1Y +39.40%
3Y -6.01%
5Y +286.50%

Key statistics

Price & volume

Prev close
32.52
Open
32.26
Day range
31.61 - 32.77
Avg price
31.90
Volume
704.93K
Turnover
22.49M
Amplitude
3.55%
52-week range
21.93 - 45.42

Valuation

P/E
-11.47
P/E (TTM)
-12.41
P/B
10.01
EPS
-2.77
Net profit
-573.25M
Net assets
656.85M

Share structure

Market cap
6.57B
Float cap
2.93B
Shares out
206.95M
Float shares
92.16M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2017-05-10
52-week range 42% of range
21.93 45.42

30.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-23.60M net over the window

Short interest

Shares short
18.55M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Immunovant (IMVT)?

Immunovant last traded at 31.77. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Immunovant's market cap?

About 6.57B.

What is the P/E ratio of Immunovant?

The trailing twelve-month P/E is -12.41. The Valuation tab shows it against the stock's own five-year range.

Does Immunovant pay a dividend?

Immunovant does not currently pay a regular dividend.

Is Immunovant a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 48.43, which implies 52.4% upside from the current price. This is not investment advice.

What is Immunovant's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Immunovant a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Immunovant discussion 0 comments

Add a comment